Current Research suggests Tirzepatide offers a dual approach, providing benefits from both GLP and GIP. A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of these incretin hormones to enhance insulin secretion, suppress glucagon release, and slow gastric emptying. This multifaceted approach helps improve blood sugar control, promotes weight loss, and reduces the risk of cardiovascular events in patients with diabetes. Tirzepatide has shown promising results in clinical trials, offering a new therapeutic option for those struggling to achieve glycemic control with existing treatments..

For Research only! You must be 21 or older.